2025. Post-Hoc Analyses Support Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Uncontrolled Eosinophilic Asthma and Prior Exacerbations. SKIN The Journal of Cutaneous Medicine. 9, 1 (Jan. 2025), s524. DOI:https://doi.org/10.25251/skin.9.supp.524.